



Advances in Ewing Sarcoma Research (AESR) 2026

Wednesday 1st July 2026, Light Auditorium, Friends House, London, UK

09.00 - 10:00	Registration	
10.00 - 10.10	Welcome, Introductions and Aims for the day	
10:10 - 10:25	A 20- Year Commitment to Ewing sarcoma research. <i>Bone Cancer Research Trust.</i>	
Session 1	Ewing Sarcoma Biology	Session 1
10.25 - 11.15	The role of EWSR1-FLI1 in Ewing sarcoma - beyond DNA control. <i>Franck Dequiedt, Director of the Laboratory of Gene expression and Cancer, Faculty of Sciences, University of Liège, Belgium.</i>	40 min keynote presentation plus 10 minutes questions
11.15 - 11.30	Developmental reprogramming in the origin of Ewing sarcoma. <i>James F Amatruda, Children's Hospital Los Angeles, USA.</i>	10 min presentation plus 5 minutes questions
11.30 - 11.45	Splicing factor 3B subunit 4 is a candidate vulnerability linked to chr1q-associated aggressive biology of Ewing sarcoma. <i>Angelina Yershova, Hopp Children's Cancer Center Heidelberg (KITZ) and German Cancer Research Center (DKFZ), Germany.</i>	10 min presentation plus 5 minutes questions
11.45 - 12.00	Interactions between FET fusion oncoproteins, SWI/SNF chromatin remodelling complexes and BRD4 in sarcoma – therapeutic opportunities. <i>Malin Lindén, Sahlgrenska center for cancer research Institute of Biomedicine, University of Gothenburg, Sweden.</i>	10 min presentation plus 5 minutes questions
Session 2	Rapid fire presentations followed by poster session and lunch	
12.00 - 14.00	Rapid fire presentations 3 min presentations followed by poster session Lunch and networking.	
Session 3	Therapeutic Opportunities in Ewing Sarcoma	
14.00 - 14.50	Overcoming the challenges of CAR T-cell immunotherapy approaches to treat solid cancers. <i>Karin Straathof, Associate Professor in Tumour Immunology, UCL Cancer Institute and honorary consultant paediatric oncologist at Great Ormond Street Hospital.</i>	40 min keynote presentation plus 10 minutes questions
14.50 - 15.05	Exploiting SAMHD1 as a Targetable Resistance Node to Unlock Fusion Protein Depletion by Cytarabine in Ewing Sarcoma. <i>Hala Habash, Karolinska Institutet, Stockholm, Sweden.</i>	10 min presentation plus 5 minutes questions
15.05 - 15.20	Targeted therapies for STAG2-mutated Ewing Sarcoma. <i>Lieke Mous, Balgrist University Hospital, University of Zürich, Switzerland.</i>	10 min presentation plus 5 minutes questions
15.20 - 15.35	Exploring ferroptosis as a novel therapeutic strategy in Ewing sarcoma. <i>Elizabeth Roundhill, Leeds Institute of Medical Research, St James's University Hospital, UK.</i>	10 min presentation plus 5 minutes questions
15.35 - 16.00	Coffee/Tea/Comfort break	
16.00 - 17.00	Build your Network/Scientific “speed dating”	Meet colleagues
17.00 - 17.10	Prize giving and Close of meeting	
17.10- 19.00	Tavistock hotel drinks and networking	